Genetically engineered Bifidobacterium shows potential for oral delivery of cancer vaccines
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. The results point to potential biomarkers that may help identify patients most likely to benefit from this approach.